Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.94 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 6/20 | 0.38 |
| ▸ | MAOB | P27338 | 5/20 | 0.36 |
| ▸ | BRD4 | O60885 | 4/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23621134 | 1.00 | SMN1; SMN2 (0.94) | SMN1; SMN2CA1CA9MAOAMAOB | |
| SCHEMBL30075317 | 1.00 | SMN1; SMN2 (0.94) | SMN1; SMN2CA1CA9MAOAMAOB | |
| SCHEMBL22001696 | 1.00 | SMN1; SMN2 (0.94) | SMN1; SMN2CA1CA9MAOAMAOB | |
| SCHEMBL20582013 | 1.00 | SMN1; SMN2 (0.94) | SMN1; SMN2CA1CA9MAOAMAOB | |
| SCHEMBL9301611 | 1.00 | SMN1; SMN2 (0.94) | SMN1; SMN2CA1CA9MAOAMAOB | |
| SCHEMBL432483 | 0.97 | — | — | |
| SCHEMBL35509 | 0.97 | — | — | |
| SCHEMBL374192 | 0.97 | — | — | |
| Potassium SCHEMBL30020888 | 0.94 | — | — | |
| Water SCHEMBL7174460 | 0.94 | SMN1; SMN2 (0.94) | SMN1; SMN2CA1CA9MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180098956-A1 | THERAPEUTIC COMPOSITIONS | BTG INT LTD (GB) | 2018-04-12 | — | — | US | disclosed |
| US-20180036274-A1 | USE OF MEDIUM CHAIN TRIGLYCERIDES FOR THE TREATMENT AND PREVENTION OF ALZHEIMER'S DISEASE AND OTHER DISEASES RESULTING FROM REDUCED NEURONAL METABOLISM II | ACCERA, INC. | 2018-02-08 | — | — | US | disclosed |
| US-20170196827-A1 | Ketone Bodies To Protect Tissues From Damage By Ionizing Radiation | TDELTAS (GB) | 2017-07-13 | — | — | US | disclosed |
| US-20170196827-A1 | Ketone Bodies To Protect Tissues From Damage By Ionizing Radiation | TDELTAS (GB) | 2017-07-13 | — | — | US | disclosed |
| EP-1778213-B1 | A METHOD FOR THE SYNTHESIS OF OLIGOMERIC COMPOUNDS | BTG INT LTD (GB) | 2017-04-05 | — | — | EP | disclosed |
| US-9603823-B2 | Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism II | ACCERA, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9579302-B2 | Ketone bodies to protect tissues from damage by ionizing radiation | TDELTAS (GB) | 2017-02-28 | — | — | US | disclosed |
| US-9579302-B2 | Ketone bodies to protect tissues from damage by ionizing radiation | TDELTAS (GB) | 2017-02-28 | — | — | US | disclosed |
| US-20160030376-A1 | Use of Genomic Testing and Ketogenic Compounds for Treatment of Reduced Cognitive Function | Cerecin Inc. | 2016-02-04 | — | — | US | disclosed |
| US-9175345-B2 | Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function | ACCERA, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20090253781-A1 | Therapeutic compositions | BTG INTERNATIONAL LIMITED (GB) | 2009-10-08 | — | — | US | disclosed |
| US-20090253781-A1 | Therapeutic compositions | BTG INTERNATIONAL LIMITED (GB) | 2009-10-08 | — | — | US | disclosed |
| US-20080287372-A1 | Use of Ketogenic Compounds for Treatment of Age-Associated Memory Impairment | ACCERA, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-7351736-B2 | Therapeutic compositions (II) | BTG INTERNATIONAL LIMITED (GB) | 2008-04-01 | — | — | US | disclosed |
| US-7351736-B2 | Therapeutic compositions (II) | BTG INTERNATIONAL LIMITED (GB) | 2008-04-01 | — | — | US | disclosed |
| US-20080009467-A1 | COMBINATIONS OF MEDIUM CHAIN TRIGLYCERIDES AND THERAPEUTIC AGENTS FOR THE TREATMENT AND PREVENTION OF ALZHEIMERS DISEASE AND OTHER DISEASES RESULTING FROM REDUCED NEURONAL METABOLISM | ACCERA, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-20070208081-A1 | Oligomeric Compounds | BTG INTERNATIONAL LIMITED (GB) | 2007-09-06 | — | — | US | disclosed |
| US-20070179197-A1 | COMPOSITIONS AND METHODS FOR IMPROVING OR PRESERVING BRAIN FUNCTION | ACCERA, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| US-20070135376-A1 | METHOD TO REDUCE OXIDATIVE DAMAGE AND IMPROVE MITOCHONDRIAL EFFICIENCY | ACCERA, INC. (US) | 2007-06-14 | — | — | US | disclosed |
| EP-1123094-B1 | THERAPEUTIC COMPOSITIONS (II) | BTG INT LTD (GB) | 2007-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208081-A1 | Oligomeric Compounds | ADH1C, LIPC, HSD17B12 | SMN1; SMN2 1461/4885CA1 566/4885CA9 2018/4885 |
| US-20180098956-A1 | THERAPEUTIC COMPOSITIONS | CPT1B, IAPP, GYS1 | SMN1; SMN2 168/4885CA1 423/4885CA9 2101/4885 |
| US-20080287372-A1 | Use of Ketogenic Compounds for Treatment of Age-Associated Memory Impairment | CPT1B, ACADM, ACAA2 | SMN1; SMN2 504/4885CA1 60/4885CA9 520/4885 |
| US-20070179197-A1 | COMPOSITIONS AND METHODS FOR IMPROVING OR PRESERVING BRAIN FUNCTION | CPT1B, ABHD6, LPL | SMN1; SMN2 73/4885CA1 1461/4885CA9 1483/4885 |
| US-20070135376-A1 | METHOD TO REDUCE OXIDATIVE DAMAGE AND IMPROVE MITOCHONDRIAL EFFICIENCY | GOT2, HADHB, HADHA | SMN1; SMN2 1050/4885CA1 3373/4885CA9 3059/4885 |
| US-20170196827-A1 | Ketone Bodies To Protect Tissues From Damage By Ionizing Radiation | ACACB, BCKDK, ACACA | SMN1; SMN2 3404/4885CA1 1332/4885CA9 1183/4885 |
| US-20080009467-A1 | COMBINATIONS OF MEDIUM CHAIN TRIGLYCERIDES AND THERAPEUTIC AGENTS FOR THE TREATMENT AND PREVENTION OF ALZHEIMERS DISEASE AND OTHER DISEASES RESULTING FROM REDUCED NEURONAL METABOLISM | ACHE, CHAT, BACE1 | SMN1; SMN2 428/4885CA1 1152/4885CA9 3114/4885 |
| US-20160030376-A1 | Use of Genomic Testing and Ketogenic Compounds for Treatment of Reduced Cognitive Function | BCKDK, HSD17B12, HSD17B10 | SMN1; SMN2 1115/4885CA1 662/4885CA9 1345/4885 |
| US-20180036274-A1 | USE OF MEDIUM CHAIN TRIGLYCERIDES FOR THE TREATMENT AND PREVENTION OF ALZHEIMER'S DISEASE AND OTHER DISEASES RESULTING FROM REDUCED NEURONAL METABOLISM II | PSEN2, MTTP, APP | SMN1; SMN2 31/4885CA1 1283/4885CA9 4203/4885 |
| US-20090253781-A1 | Therapeutic compositions | CPT1B, GYS1, IAPP | SMN1; SMN2 190/4885CA1 420/4885CA9 2004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.